

JOB OFFERS IN QUANTITATIVE PRECLINICAL PET

1 PHD CANDIDATE

PhD Project: Quantitative preclinical PET and SPECT





Position: Full-time employment contract for 3 years

Requirements: Undergraduate studies in Physics, Mathematics, Biomedical Engineering...

Desirable requirements: high academic records and/or MSc in Biomedical Sciences

Project: Preclinical PET and SPECT quantification is of outstanding importance as a basis for the generation of reliable image-based biomarkers for clinical routine and preclinical research. However, accurate image quantification is challenging and requires many technical and biological factors to be considered. This project is focused on implementing molecular imaging quantification tools (PET and SPECT) and investigating main factors affecting imaging biomarkers derived from PET/SPECT studies, mainly using monoclonal antibodies, nanobodies, peptides...

The potential of the so-called quantitative preclinical PET approach lies in the fact that detected disease-specific molecules can be used both as diagnostic and targets for radionuclide therapies. Our mission is towards the development of new theragnostic radiopharmaceuticals based on peptides and monoclonal antibodies radiolabelled with diagnostic and therapeutic radioisotopes.



Please contact to: pablo.aguiar@usc.es

MIBIOPHARM GROUP (Molecular imaging biomarkers and theragnosis)

Our research is centred on developing PET imaging biomarkers and theragnostic approaches through implementation of image quantification strategies and kinetic modelling methods of new radiopharmaceuticals. Our translational research covers from the preclinical area (focused on novel theragnostic approaches based on image-guided therapies, preclinical imaging and kinetic modelling) to the clinical area (focused on new imaging biomarkers for early diagnosis and follow-up of human diseases: harmonization, standardization, and quantification of clinical PET biomarkers).

In addition, we manage an imaging facility aimed at developing preclinical imaging biomarkers and radiolabelling procedures to contribute to the successful translation of drugs from animal models to patients (microPET/SPECT/CT Albira Bruker, microPET/MR 3T Biospec Bruker and microCT Skyscan Bruker)

Pablo Aguiar Fernández pablo.aguiar@usc.es

CIMUS, Campus Vida Avenida Barcelona, s/n, 15782, Santiago de Compostela, A Coruña

